Drawing for NOMIG

USPTO serial 75755912

NOMIG

Reviewed by CopyMark Law Group

Status 601
Filing date
Status date
Registration date
—
Examiner
DALIER, JOHN DAVID
Law office
FILE REPOSITORY (FRANCONIA)

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with NOMIG?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

H. John Campaign

H JOHN CAMPAIGN GRAHAM, CAMPAIGN PC36 W 44TH STNEW YORK, NY 10036-8178UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005PHARMACEUTICAL PREPARATIONS AND SUBSTANCES FOR USE IN THE TREATMENT OF DISEASES AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM, THE PERIPHERAL NERVOUS SYSTEM AND THE CARDIOVASCULAR SYSTEM; PHARMACEUTICAL PREPARATIONS AND SUBSTANCES FOR PAIN CONTROL, ANESTHESIA, URINARY INCONTINENCE AND AN OVERACTIVE BLADDERACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Feb 25, 2001ABN1ABANDONMENT - EXPRESS MAILED—
Oct 12, 2000CNSLLETTER OF SUSPENSION MAILED—
Sep 20, 2000CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 8, 1999CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 1, 1999DOCKASSIGNED TO EXAMINER—
Oct 27, 1999DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance